A spergillus fumigatus is the most common cause of invasive aspergillosis afflicting various immunocompromised patients. We report 2 cases of documented invasive disease in children in the United States caused by A. viridinutans, a fumigati-mimetic mold, which produced clinical manifestations distinct from A. fumigatus.
The Patients
Patient 1 was a 14-year-old boy with p47 phox -deficient chronic granulomatous disease. He had Staphylococcus aureus liver abscesses at ages 5 and 10 years, Burkholderia cepacia complex pneumonia at age 6 years, and Serratia marcescens pneumonia at age 12 years. In February 2004, while the patient was receiving itraconazole prophylaxis, right-sided chest pain and fever developed. A computed tomography (CT) scan showed a 2-cm right middle lobe nodule adjacent to the cardiac border and mediastinal lymphadenopathy abutting the superior vena cava and anterior pericardium (Figure 1 ). Lymph node biopsy yielded a mold morphologically identified as A. fumigatus. Treatment with voriconazole was initiated. Repeat imaging 1 week later showed slight enlargement of the mediastinal mass. One month later, there was continued enlargement of the lung nodule and mediastinal adenopathy with necrosis. Caspofungin was added. Two weeks later, a new right middle lobe infiltrate was noted. Antifungal therapy was changed to posaconazole. Over the next 2 months, there was expansion of the right lung infiltrates and lymphadenopathy. Treatment was modified to posaconazole and caspofungin. Serial imaging over the next 3 weeks showed regression of the lung consolidations and mediastinal mass. Four months later, with ongoing resolution of the thoracic disease, the patient began receiving a maintenance dosage of posaconazole. As of 5 years later, he had experienced no recurrence.
Patient 2 was an 8-year-old boy with hyperimmunoglobulin-E (Job) syndrome due to mutation in signal transducer and activator of transcription-3 in whom a right-sided pulmonary abscess developed and failed to improve after 1 month of antibacterial therapy. New left lung nodules were biopsied and specimens yielded a mold morphologically identified as A. fumigatus. During 3 months of treatment with voriconazole, the bilateral pulmonary lesions cavitated. Two months later, left lower lobe wedge resection yielded the same mold. Diaphragmatic injury required primary closure with sutures. One month later, enlargement of the residual left lung lesions prompted change in therapy to amphotericin B and caspofungin. Following the patient's transfer to the National Institutes of Health, imaging showed left apical and lower lobe cavitary masses, left pleural mass and effusion, and a right upper lung cavity with nodule. Samples taken from the left lower cavity and pleura demonstrated septated branching hyphae; specimens grew a mold resembling A. fumigatus. Amphotericin B-related nephrotoxicity prompted change of treatment drug to posaconazole. Tissues obtained through subsequent surgical debridements of lung, pleural, diaphragmatic, and subpulmonic abscesses, left lower lobe segmentectomy, and decortication all grew a mold morphologically consistent with A. fumigatus. The patient's medical regimen was changed to posaconazole, caspofungin, and flucytosine. Persistent pleural tube drainage yielded the same fungus, despite treatment with amphotericin B and granulocyte intrapleural infusions. Systemic granulocyte infusions, adjunctive granulocytecolony stimulating factor, and interferon-γ led to transient stabilization of disease. However, progressive splenic abscess formation contiguous with the diaphragm was noted (Figure 2 ). Seven months later, Guillain-Barré syndrome without a clear cause developed in the patient. The patient died of progressive respiratory failure with aspiration of abscess cavity content. Autopsy demonstrated extensive fungal abscesses in the lungs and left pleural space that extended into the airways, diaphragm, and spleen.
Isolates were initially identified by morphologic criteria using standard clinical mycology laboratory media and incubation conditions. Subsequently, multilocus sequence analyses were performed and targeted the internal tran- (8) . This in vitro resistance may explain in part the refractory disease seen clinically. Furthermore, synergistic studies of isolates from patient 2 with the combination of either posaconazole and terbinafine or amphotericin B and terbinafine produced an indifferent effect.
Conclusions
Differentiation of species within Aspergillus section Fumigati using phenotypic features alone is difficult. Our isolates resembled A. fumigatus but demonstrated slower growth at 37°C and markedly reduced sporulation. Based on multilocus sequence analyses, however, these isolates are A. viridinutans, a mold phenotypically resembling but phylogenetically distinct from A. fumigatus. Although the ITS region failed to distinguish these isolates from A. fumigatus, weak intrataxon discriminatory capacity has been previously reported for this locus (9) . β-tubulin and calmodulin sequences confirmed its identification as A. viridinutans. Sequence divergence within our isolates is consistent with findings from previous studies demonstrating intraspecific genetic variability within the A. viridinutans species (10) (11) (12) .
A. viridinutans was originally isolated from rabbit dung in Australia and has since been identified in soil samples globally (12, 13) . Although A. viridinutans has been reported from retrospective analysis of culture collections (9) (10) (11) , its clinical relevance has not been defined. These cases demon- strate that A. viridinutans can cause a distinct form of aspergillosis, characterized by chronicity, propensity to spread in a contiguous manner across anatomical planes, and relative refractoriness to antimycotic drugs. In contrast, invasive aspergillosis affecting neutropenic chemotherapy or transplant patients is typically an acute disease with predilection for angioinvasion and hematogenous dissemination; successful response to antifungal therapy most commonly occurs within the first 6 weeks of treatment (14) . However, A. viridinutans infections in 2 patients with distinct primary immunodeficiencies suggest that these clinical phenomena reflect inherent pathogenic features of the mold, rather than manifestations due to a specific immune defect. A similar constellation has been described for another cladistically related fumigati-mimetic, Neosartorya udagawae, in patients with chronic granulomatous disease or myelodysplasia (15) , which may suggest pathogenetic differences between subgroups within section Fumigati. Thus, genotypic-based identification of fumigati-mimetic fungi may have implications for clinical course and management. 
